Brent Blackburn

Dr. Blackburn was Senior Vice President, Drug Discovery & Development at CV Therapeutics, a biopharmaceutical company devoted to the discovery and development of drugs for cardiovascular diseases. In 1997, Dr. Blackburn joined CV Therapeutics to head its drug discovery unit, expanding his responsibilities in 2004 to include leading the clinical research and biometrics groups. While at CVT, the company successfully developed and commercialized two drugs and placed seven products into development for multiple cardiovascular and metabolic indications. Importantly, Dr Blackburn was a leading member of the team that discovered and developed regadenoson in the United States and Europe. Dr Blackburn devised the clinical development program and participated in every facet of the development of regadenoson. In 2009 Gilead Sciences acquired CV Therapeutics. He has authored over 40 publications and is an inventor of more than 20 US patents. Dr. Blackburn earlier served as a Scientist at Genentech and received his BS in Chemistry from Texas Christian University and his PhD from the University of Texas at Austin, which was followed by post-doctoral appointments at Oxford University (UK) and Massachusetts Institute of Technology prior to joining Genentech, Inc.